Page 3 - reflections_dyslipidaemia_newsletter9_Final
P. 3
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #9 2025
The addition of Lp(a) values to the PREVENT equations
somewhat improved personalised risk assessment, particularly CLINICAL PEARLS FROM THE FACULTY Dyslipidaemia
within specific subgroups like lower-risk individuals for CHD
and borderline-risk individuals for ASCVD. However, this
analysis demonstrated that while the novel PREVENT equations
performed well for risk prediction in individuals with and without
elevated Lp(a), Lp(a) levels remain independently associated
with higher cardiovascular risk. Given that Lp(a) is currently
tested at low rates but is an actionable risk enhancer, these
findings suggest that more widespread Lp(a) testing may be
beneficial for further personalising risk assessment and guiding
more aggressive risk factor modification, even with the adoption
of the new PREVENT equations.
WATCH
PROF. CRISTINA GAVINA DISCUSS
CLICK HERE THE CLINICAL RELEVANCE OF THIS
FOR THE LINK TO FULL ARTICLE ARTICLE.
Clinical staging to guide management of metabolic disorders and their sequelae: a
European Atherosclerosis Society consensus statement.
Romeo S, et al. Eur Heart J. 2025 May 7:ehaf314. doi: 10.1093/eurheartj/ehaf314. Online ahead of print.
Global obesity rates among adults have surged between 1990 and 2022 and a lot of evidence suggests that excess adiposity results
in several systemic abnormalities. It is being increasingly recognised that the various metabolic risk factors of these abnormalities
are interconnected, but most efforts to address this topic have focused on the burden and implications, which haven’t translated into
better patient care. The European Atherosclerosis Society (EAS) Consensus panel convened to propose a physiologically based
clinical staging system based on diverse data for systemic metabolic disorders (SMDs) to facilitate improved awareness, tailored
treatment approaches, and ultimately reduce the burden of obesity-related comorbidities.
Graphical abstract
A: prediabetes; B: overweight;
C: liver steatosis; D: hypertension;
E: dyslipidaemia; F: type 2
diabetes; G: asymptomatic
diastolic dysfunction; H: metabolic-
associated steatohepatitis;
I: chronic kidney disease; J:
subclinical atherosclerosis
TABLE OF CONTENTS
